创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology: What are the characteristics of a non-GLP toxicology platform?

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-14 13:31
  • Views:

(Summary description)Toxicology research plays a crucial role in drug discovery, biotechnology, and various research programs. It is able to assess the potential hazards of chemicals, drugs, environmental pollutants, etc. to the human body or the ecosystem. However, traditional GLP (Good Laboratory Practice) toxicology platforms are often limited by strict regulations, complex operational procedures and high costs. The non-GLP toxicology platform launched by InnoModels Biotechnology, with its unique advantages, has revolutionized the field of scientific research and drug discovery

InnoModels Biotechnology: What are the characteristics of a non-GLP toxicology platform?

(Summary description)Toxicology research plays a crucial role in drug discovery, biotechnology, and various research programs. It is able to assess the potential hazards of chemicals, drugs, environmental pollutants, etc. to the human body or the ecosystem. However, traditional GLP (Good Laboratory Practice) toxicology platforms are often limited by strict regulations, complex operational procedures and high costs. The non-GLP toxicology platform launched by InnoModels Biotechnology, with its unique advantages, has revolutionized the field of scientific research and drug discovery

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-03-14 13:31
  • Views:
Information

Toxicology research plays a crucial role in drug discovery, biotechnology, and various research programs. It is able to assess the potential hazards of chemicals, drugs, environmental pollutants, etc. to the human body or the ecosystem. However, traditional GLP (Good Laboratory Practice) toxicology platforms are often limited by strict regulations, complex operational procedures and high costs. The non-GLP toxicology platform launched by InnoModels Biotechnology, with its unique advantages, has revolutionized the field of scientific research and drug discovery.
Flexibility and Efficiency
The biggest advantage of InnoModels' non-GLP toxicology platform is its high flexibility and efficiency. Compared to traditional GLP platforms, non-GLP platforms do not need to comply with stringent regulatory requirements, which greatly simplifies the operational process and approval procedures. This means that researchers can conduct experiments more quickly, shortening the R&D cycle and improving research efficiency.
Cost-effectiveness
Cost is a key factor constraining many research projects and drug development. InnoModels' non-GLP toxicology platform has significant advantages in cost control. Since there is no need to follow GLP standards, the platform can save a lot of costs on compliance audits, laboratory construction and equipment purchases. This makes high-quality toxicology research affordable for more research institutions and companies.

 


Customized Services
InnoModels Bio's non-GLP toxicology platform also provides personalized and customized services. According to the specific needs and experimental requirements of customers, the platform can provide customers with tailor-made experimental programs, data analysis and interpretation and other services. This customized service can better meet the scientific research needs of customers and improve the relevance and effectiveness of experiments.
Rapid Response and Innovation
In the rapidly developing field of scientific research and drug discovery, rapid response and innovation capability are crucial. InnoModels Bio's non-GLP toxicology platform has strong rapid response and innovation capabilities. The platform can quickly adapt to new research needs and technological development, providing customers with the latest and most effective toxicology research methods and technical support.
Wide range of applications
InnoModels Bio's non-GLP toxicology platform is not only suitable for drug research and development, but also widely used in cosmetics, food, environmental protection and other fields. The platform can provide customers with comprehensive toxicology evaluation services to help them understand the safety, stability and potential risks of their products.
In summary, InnoModels' non-GLP toxicology platform has injected new momentum into the field of scientific research and drug discovery with its advantages of flexibility, cost-effectiveness, customized services, rapid response and innovation capabilities, and a wide range of applications. In the future, with the continuous progress of science and technology and the growing demand for scientific research, we have reason to believe that the non-GLP toxicology platform of InnoModels Biotechnology will play an even more important role in promoting scientific research and innovation as well as drug discovery and development.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司